Trainer:Visage Training Academy, 562 Prescot Road, Old Swan, Liverpool L13 3DE (facing the Post Office near Tesco) - LaurenAshley owner of Visage Aesthetics
DOI: 10.1016/j.mam.2004.06.006 Rubin, M
Your provider will guide you on the best dosing schedule for your goals
What Experts Say GLP-1 RAs are clinically approved and have a strong safety record when used as prescribed
The field is evolving quickly, with new, more effective options and research emerging constantly
[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)